EXEL outlines transition strategy through 2026, leveraging CABOMETYX
Management outlined a transition strategy through 2026: maximize CABOMETYX and invest in zanzalintinib to offset post-2031 LOE. CABOMETYX targets $3B peak sales; zanzalintinib is launch-ready for CRC, with capital allocation balancing R&D, BD and share buybacks.